Hansa Biopharma AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HNSBF research report →
Companywww.hansabiopharma.com
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy.
- CEO
- Renee Aguiar-Lucander
- IPO
- 2015
- Employees
- 138
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $245.80M
- P/E
- -4.96
- P/S
- 14.32
- P/B
- -12.41
- EV/EBITDA
- -5.87
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 59.68%
- Op Margin
- -299.07%
- Net Margin
- -361.44%
- ROE
- 201.60%
- ROIC
- -59.99%
Growth & Income
- Revenue
- $222.26M · 29.74%
- Net Income
- $-534,110,000 · 33.79%
- EPS
- $-6.55 · 48.99%
- Op Income
- $-517,797,000
- FCF YoY
- 18.64%
Performance & Tape
- 52W High
- $4.58
- 52W Low
- $2.73
- 50D MA
- $2.90
- 200D MA
- $3.11
- Beta
- 1.50
- Avg Volume
- 7
Get TickerSpark's AI analysis on HNSBF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HNSBF Coverage
We haven't published any research on HNSBF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HNSBF Report →